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was tested by Student’s t-test. The Papp (A to B) 
significantly higher than Papp (B to A) at p<0.05 (p = 
0.0128), indicating an active uptake mechanism. 
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Figure 5.16 Apparent permeability coefficients, Papp (A to B) and Papp 
(B to A) for donepezil. Permeation studies were performed 
in triplicate in three independent experiments. Data are 
expressed as mean Papp ± SEM (x10-6 cm/s). Efflux ratio 
(ER) was calculated by the equation Papp (B-A)/Papp (A-B). 
Statistical significance of differences was tested by 
Student’s t-test. No significant difference at p<0.05, 
indicating passive permeation. 
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Figure 5.17 Apparent permeability coefficients, Papp (A to B) and Papp 
(B to A) for digoxin (a P-gp substrate involving efflux 
mechanism). Permeation studies were performed in 
triplicate in three independent experiments. Data are 
expressed as mean Papp ± SEM (x10-6 cm/s). Efflux ratio 
(ER) was calculated by the equation Papp (B-A)/Papp (A-B). 
Statistical significance of differences was tested by 
Student’s t-test. The Papp (B to A) significantly higher than 
Papp (A to B) at p<0.05 (p = 0.0367), indicating an active 
efflux transport. 
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Figure 5.18 Apparent permeability coefficients, Papp (A to B) and Papp 
(B to A) for sucrose (a paracellular marker). Permeation 
studies were performed in triplicate in three independent 
experiments. Data are expressed as mean Papp ± SEM 
(x10-6 cm/s). Efflux ratio (ER) was calculated by the 
equation Papp (B-A)/Papp (A-B). Statistical significance of 
differences was tested by Student’s t-test. No significant 
difference between the Papp values at p<0.05, indicating a 
passive paracellular permeation. 
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Figure 5.19 Blood-brain barrier (BBB) in vivo and in vitro. (A) 
Aqueous boundary layer (ABL) is minimal due to a high 
velocity capillary blood flow. (B) Presence of ABL 
adjacent to the cell membrane due to inefficient stirring 
during permeability assay. 
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Figure 5.20 Derivation of the intrinsic transcellular permeability, P0 
from apparent permeability, Papp of aurone 4-3 using 
pܭ௔୊୐୙ଡ଼ method in pCEL-X software. The Papp measured 
for aurone 4-3 were analyzed to derive the P0 value 
corrected for aqueous boundary layer (ABL) effect and 
paracellular permeability. The black round dots are the 
logPapp is the logarithm of measured Papp of aurone 4-3. 
Permeability through the ABL, logPABL was determined 
using [3H] propanolol permeability as marker. The filter 
limits, logPfilter were from porosity of blank polycarbonate 
filter membrane without cells. Paracellular permeability, 
logPpara, was determined using [14C]sucrose permeability. 
Transcellular permeability, logPc was generated with the 
curve maximum indicating the intrinsic transcellular 
permeability in logarithm, logP0 of aurone 4-3. The 
sigmoidal solid curves (log permeability-pH) were fitted to 
the measured logPapp and simultaneously refined with the 
fixed contributors: PABL, Pfilter and Ppara by a weighted 
nonlinear regression to derive intrinsic transcelullar 
permeability, P0. Each data point was determined from 
three independent experiments and each experiment with n 
= 3 filter inserts. 
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Figure 6.1 Structure of aurone 4-3 
 
177 
Figure 6.2 Diagram showing the drug treatment (4-3 HCl) schedule 
and scoring of the paralysis assay. 
 
184 
Figure 6.3 Effects of 4-3 HCl on the Aβ-induced paralysis in 
GMC101. Time refers to hours after temperature up-shift. 
Incorporation of 4-3 HCl into the agar media delayed the 
onset of paralysis, also suppressed the Aβ-induced 
paralysis (untreated vs. 100μM, p<0.0001***; untreated vs. 
50μM, p<0.0001***; untreated vs. 25μM, p=0.0045**, 
paired log rank survival test). Data are expressed as 
percentage of non-paralysed worms from at least three 
independent assays of > 100 worms in each experiment  
(n = 3). The plot shown is representative of three 
experiments. Error bars = SEM. 
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Figure 6.4 Diagram illustration showing the drug administration 
(4-3 HCl) time period and scoring of the neuronal death. 
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Figure 6.5 Representative images of the head region of worms with 
GFP expression pattern of DAergic neurons of C. elegans 
strain UA57, (A) worms with intact DAergic neurons, and 
(B-C) worms with patterns of DAergic neurons lost or 
degenerated. The left side shows the fluorescence images. 
The right side shows the differential interference contrast 
(DIC) images.  
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Figure 6.6 Quantification of worms with intact DAergic neurons 
(without neurotoxin exposure). The transgenic strain 
UA57, raised in the presence or absence of 4-3 HCl (25, 
50 and 100 μM) on NGM plates from synchronized eggs to 
L1 stage for 19 h and further incubated for 72 h without 
the exposure to 6-OHDA. Data were presented as the mean 
percentage of worms with intact DAergic neurons from at 
least three independent assays (n = 3) of > 100 worms in 
each experiment. Error bars = SEM.  
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Figure 6.7 Quantification of worms with intact DAergic neurons. The 
L1 worms of the transgenic strain UA57, raised in the 
presence or absence of 4-3 HCl (25, 50 and 100 μM) from 
synchronized eggs, were exposed to the 6-OHDA and 
further incubated for 72 h in the presence or absence of 4-3 
HCl (25, 50 and 100 μM). Data were presented as the 
mean percentage of worms with intact DAergic neurons 
from at least three independent assays of >100worms in 
each experiment. Error bars = SEM. A hash (#) indicates 
significant differences between 6-OHDA-treated and 
untreated animals (p<0.0001); an asterisk (*) indicates 
significant differences between the 6-OHDA-treated 
control and 4-3 HCl + 6-OHDA-treated samples (*p<0.05, 
****p<0.0001). 
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Figure 7.1 Aurones 2-2 and 4-3 with multitargeting potential. 
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Figure 7.2 Proposed new “fluoroaurones” based on 4-3. 
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AURON DENGAN KEFUNGSIAN AMINA DAN KARBAMAT SEBAGAI 
AGEN NEUROPROTEKTIF DENGAN POTENSI PELBAGAI SASARAN: 
SINTESIS DAN KAJIAN HUBUNGAN STRUKTUR-AKTIVITI 
SERTA MOD TINDAKAN 
 
ABSTRAK 
 
Penyakit Alzheimer (AD) ialah penyakit kompleks pelbagai faktor melibatkan 
pelbagai mekanisme yang menyumbang kepada pencetusan penyakit ini. Dalam 
pencarian entiti kimia baru untuk menangani faktor-faktor penyebab penyakit ini, 
strategi rekaan ligan diarah pelbagai sasaran (MTDL) telah digunakan dalam kajian 
ini dengan menggabungkan motif struktur yang terpilih (pelbagai amina dan 
karbamat) daripada dua ubat Alzheimer yang mantap (donepezil dan rivastigmina) ke 
dalam perancah auron. Auron-auron ini direka berdasarkan premis bahawa perancah 
tersebut berpotensi digunakan untuk membangunkan suatu sebatian pelbagai sasaran 
yang bersaiz munasabah kecil untuk neuroprotektif sementara memelihara ciri-ciri 
menyerupai ubat yang baik. Dalam kajian ini, suatu siri terbitan auron yang 
membawa kefungsian amina dan karbamat di pelbagai kedudukan (gelang A dan/atau 
B) perancah telah disintesiskan dan dicirikan dengan menggunakan teknik-teknik 
spektroskopi. Auron-auron tersebut pada mulanya dinilai dalam aktiviti in vitro 
perencatan asetilkolinesterase (AChE) dan butirilkolinesterase (BuChE). Untuk 
mengesahkan ciri pelbagai sasaran mereka, auron tersebut dinilai dalam dua aktiviti 
berkaitan dengan penyakit Alzheimer (AD), iaitu perencatan monoamina oksidase 
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(MAO) dan pengagregatan amiloid beta (Aβ). Pada masa yang sama, kestabilan 
metabolik dan ketelapan rintangan darah-otak (BBB) auron terpilih yang poten 
diperiksa untuk mengenal pasti suatu sebatian optimum dengan kombinasi pelbagai 
potensi dan profil farmakokinetik yang baik. Kesan neuroprotektif aurone 4-3 yang 
paling baik kemudian diperiksa dengan dua model neurodegenerasi Caenorhabditis 
elegans (C.elegans), iaitu kelumpuhan diaruh Aβ dan neurodegenerasi diaruh 
6-hidroksidopamina (6-OHDA). Kajian hubungan struktur-aktiviti mendedahkan 
beberapa perencat kuat AChE selektif yang membawa moieti piperidina dan 
pirolidina di gelang A atau B, dengan nilai-nilai IC50 submikromolar. Sebagai 
tambahan kepada aktiviti perencatan AChE mereka, potensi pelbagai sasaran telah 
diperhatikan dalam dua auron, iaitu auron 2-2 (perencat MAO-B) dan 4-3 (perencat 
pengagregatan Aβ). Pengeraman mikrosom hati tikus dengan auron mengenalpasti 
4-3 sebagai paling stabil secara metabolik berbanding dengan auron-auron lain. 
Penilaian ketelapan BBB menggunakan cerakinan ketelapan membran tiruan selari 
(PAMPA) dan ketelapan dwiarah sel endothelium otak khinzir (PBEC) mendedahkan 
kesemua auron yang diuji sangat telap secara pasif merentasi BBB serta penerapan 
aurone 4-3 adalah melibatkan mekanisme pengambilan aktif merentasi BBB. 
Tambahan, auron 4-3 yang menjanjikan juga menunjukkan perlindungan kepada 
nematod daripada ketoksikan diaruh Aβ dan 6-OHDA dalam model neurodegenerasi 
C.elegans. Maka, auron 4-3 yang ditemui dalam kajian ini mewakili suatu sebatian 
petunjuk menyerupai ubat yang menjanjikan kepada perkembangan lanjut perancah 
auron sebagai agen pelbagai poten yang berpotensi untuk penyakit neurodegeneratif. 
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AURONES OF AMINE AND CARBAMATE FUNCTIONALITIES AS 
NEUROPROTECTIVE AGENTS WITH MULTITARGETING POTENTIAL: 
SYNTHESIS, STRUCTURE-ACTIVITY RELATIONSHIPS AND 
MODE OF ACTION STUDIES 
 
ABSTRACT 
 
Alzheimer’s disease (AD) is a complex multifactorial disease involving diverse 
mechanisms contributing to the onset of the disease. In the search for novel chemical 
entities to address the causative factors of the disease, the multitarget-directed ligand 
(MTDL) design strategy has been applied in the present study by incorporating 
selected structural motifs (various amines and carbamate) from two established 
Alzheimer drugs (donepezil and rivastigmine) into the aurone scaffold. These 
aurones were designed on the premise that the scaffold could be utilised to develop a 
reasonably small sized multitargeting compound (targeting cholinesterase, 
monoamine oxidase, and amyloid-beta aggregation) for neuroprotection while 
maintaining good drug-like properties. In this study, a series of aurone derivatives 
carrying amine and carbamate functionalities at various positions (ring A and/or B) 
of the scaffold was synthesized and characterized using spectroscopic techniques. 
These aurones were initially evaluated for their in vitro acetylcholinesterase (AChE) 
and butyrylcholinesterase (BuChE) inhibitory activities. To further substantiate their 
multi-targeting properties, the aurones were evaluated on two Alzheimer’s disease 
(AD)-related activities, namely monoamine oxidase (MAO) and amyloid-beta (Aβ) 
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aggregation inhibitions. In parallel, the metabolic stability and blood-brain barrier 
(BBB) permeability of selected potent aurones were examined to identify an optimal 
compound with a combination of multipotency and favourable pharmacokinetic 
profile. The neuroprotective effect of the most promising aurone 4-3 was then 
examined on two Caenorhabditis elegans (C. elegans) neurodegeneration models, 
namely Aβ-induced paralysis and 6-hydroxydopamine (6-OHDA)-induced 
neurodegeneration. Structure-activity relationship study revealed several potent 
selective AChE inhibitors carrying piperidine and pyrrolidine moieties at ring A or B, 
with submicromolar IC50 values. In addition to their AChE inhibitory activity, 
multi-targeting potential was observed in two aurones, namely aurone 2-2 (MAO-B 
inhibitor) and 4-3 (Aβ-aggregation inhibitor). Rat liver microsomal incubation of the 
aurones identified aurone 4-3 to be the most metabolically stable compared to the 
other aurones. BBB permeability evaluation using the parallel artificial membrane 
permeability assay (PAMPA) and porcine brain endothelial cells (PBEC) 
bidirectional permeability revealed all the tested aurones to be highly passive 
permeable across the BBB and the permeation of aurone 4-3 to involve active uptake 
mechanism across the BBB. In addition, the most promising aurone 4-3 also showed 
protection on the nematodes against both Aβ- and 6-OHDA-induced toxicities in the 
C.elegans neurodegeneration models. Hence, aurone 4-3 discovered in the present 
study represents a promising, drug-like lead for further development of the aurone 
scaffold as potential multi-potent agents for neurodegenerative diseases. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Neurodegenerative diseases 
Neurodegenerative diseases are debilitating disorders characterized by progressive 
loss of nerve structure and function in the central nervous system (CNS). They 
include Alzheimer’s disease (AD), Parkinson’s disease, Huntington’s disease, 
amyotrophic lateral sclerosis and multiple sclerosis. Although there are a variety of 
risk factors (aging, genetics, environment, and lifestyle) leading to the onset of these 
diseases (Nieoullon, 2011), the outcome is the same: loss of cognitive function and 
motor control progressing to brain atrophy and death (Brettschneider et al., 2015). 
Despite their enormous diversity in clinical manifestations and pathogenesis, most 
neurodegenerative diseases share some common key features: dramatic loss of 
synapses and neurons and cerebral deposits of insoluble misfolded protein aggregates 
(Forman et al., 2004). These deposits can be considered trademarks for the different 
neurodegenerative disorders because the main protein component involved is 
different in each disease (Ramanan and Saykin, 2013). In the particular case of AD, 
two types of protein deposits are considered to be the pathological hallmarks of the 
disease, namely senile plaques (also known as amyloid plaques) that are associated 
with extracellular amyloid beta (Aβ) protein (Glenner and Wong, 1984) and 
intracellular neurofibrillary tangles (NFT) that are composed of hyperphosphorylated 
tau protein (Huang and Mucke, 2012; Longo and Massa, 2004). 
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1.1.1 Prevalence and pathogenesis of AD 
Among the various neurodegenerative diseases that have been diagnosed, AD stood 
out to be the most prominent in terms of prevalence and socioeconomic burden 
(Maslow, 2008). The disease is named after Alois Alzheimer, the pathologist who in 
1907 first observed the plaques and tangles in the brains of AD patients (Forman et 
al., 2004). It is age-related and affects approximately 5 - 8 % of people over the age 
of 65, 15 - 20 % of those over the age of 75, and 25 - 50 % of those over the age of 
85 (Shah et al., 2008). Epidemiologic studies show that around 35 million in the 
world are suffering from AD and this will grow to more than 100 million cases by 
2050 (Aggarwal et al., 2012; Thies and Bleiler, 2013). In parallel with the increase in 
the number of people affected with AD, the annual financial cost to society due to 
AD in 2010 was estimated approximately US$ 604 billion worldwide (Wimo et al., 
2013) and expected to increase by the year of 2030 (Abbott, 2011), highlighting the 
enormous socioeconomic impact of AD.  
 
 Notwithstanding the many efforts to understand the AD pathogenesis, the 
precise aetiology of AD remains incomplete (Leon et al., 2013). Advancements in 
molecular biology and immunology over the past two decades have enabled further 
understanding of the disease and the identification of molecular targets that mediate 
the pathogenesis of AD. Several theories have come into prominence to explain the 
aetiology of AD (Klafki et al., 2006; Suh et al., 2005): the cholinergic deficit 
hypothesis (Bartus et al., 1982), the amyloid cascade hypothesis (Hardy and Allsop, 
1991; Hardy and Selkoe, 2002; Karran et al., 2011), oxidative stress and 
mitochondrial dysfunction (Garcia-Escudero et al., 2013; Marcus et al., 1998; 
Moreira et al., 2010), excitotoxic and neuroinflammatory processes (Mishizen-
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Eberzet al., 2004) and monoaminergic abnormalities (Baker and Reynolds, 1989, 
Trillo et al., 2013), altogether depicting a complex picture of the disease. 
 
The cholinergic hypothesis is particularly important as it has been the 
cornerstone to the discovery of the present treatments for AD. This hypothesis 
postulates that the cognitive impairment and symptoms (dementia, memory loss) 
experienced by AD patients are due to the extensive loss of cholinergic neurons in 
certain regions of the brain such as the hypothalamus, the amygdala, and the 
neocortex. Drugs that can restore this cholinergic deficit in the CNS would therefore 
be able to slow the cognitive decline associated with the disease. 
 
Also of prominence is the amyloid cascade hypothesis which originates from 
the observation of Aβ plaques in the AD brains. The deposition of insoluble Aβ 
fibrils amidst the neurons and the generation and aggregation of Aβ monomers into 
protofibrils and oligomers have been shown in studies in vitro and in vivo to be toxic 
to the neurons (Klein, 2013). The mechanisms by which Aβ exerts neuronal toxicity 
and the identification and dynamics of the different Aβ forms (for examples, 
protofibrils, soluble oligomers) that are toxic are among the most extensively studied 
subjects in AD research with the aim of finding a potential therapeutic targeting Aβ 
in mind (Benilova et al., 2012).  
 
1.1.2 Current treatment modalities for AD 
To date, there is no efficacious treatment available that allows the recovery and 
reversal of the inevitable degenerative process of AD (Simoes et al., 2014). Current 
drugs available for AD treatment in the clinic are mainly acetylcholinesterase 
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inhibitors (AChEIs) (Leon et al., 2013) based on the cholinergic deficit hypothesis. 
This hypothesis arised from evidence that AD patients suffered from cognitive 
dysfunction because of the loss of cholinergic neurons and activity in certain parts of 
the brain. Thus, a drug that inhibits the hydrolysis of the cholinergic neurotransmitter 
acetylcholine by presynaptic acetylcholinesterase would augment cholinergic activity 
and relieve the symptoms of AD. Only a handful of AChEIs have been approved by 
the U.S. Food and Drug Administration (FDA) and launched in the market for the 
treatment of mild and moderate stages of AD. They are tacrine (1993), donepezil 
(1996), rivastigmine (2000) and galanthamine (2001) (Hong-Qi et al., 2012). Tacrine 
was the first acetylcholinesterase inhibitor approved for the treatment of AD 
(Tumiatti et al, 2010). However, tacrine was eventually abandoned due to its limited 
therapeutic use because of its poor oral bioavailability and severe adverse effects 
such as hepatotoxicity and gastrointestinal reactions (Alfirevic et al., 2007; Mehta et 
al., 2012).  
 
In 2003, another drug called memantine has been approved by FDA that acts 
as a non-competitive antagonist of glutamate receptors (Mehta et al., 2012; Rodda 
and Carter, 2012).  This drug marks a departure from the previous AChEIs in that it 
has a different mechanism of action; it binds to the N-methyl-D-aspartate (NMDA) 
receptor to block the excitotoxic effects of elevated glutamate levels that may lead to 
neuronal dysfunction (Rodda and Carter, 2012).  
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Figure 1.1: Chemical structures of clinically used drugs for the treatment of AD. 
 
1.1.3 Emerging paradigm: Multitarget-directed ligand (MTDL)  
The current drugs available for AD are considered as short-term treatments and 
appear to be palliative as they temporarily slow down the progressive loss of 
cognitive function and do not address AD’s causative factors (Hong-Qi et al., 2012; 
van Marum, 2008). The molecular basis of AD can be considered as a complex 
network of protein targets with multiple pathological pathways inter-relating with 
each other (Minarini et al., 2012). Due to the multifactorial nature of AD and the 
diverse molecular and cellular mechanisms implicated in the disease, these “one-
drug-one-target” drugs are only capable of symptomatic relief and are unable to 
prevent the neurodegenerative process hence the limited efficacy of the current 
clinical therapy for AD (Pisani et al., 2011). The lack of effective treatment of the 
disease in spite of the complexity of AD prompted many research efforts to search 
for potential disease-modifying agents that target the other factors associated with 
AD (Citron, 2010; Galimberti and Scarpini, 2011; Salomone et al., 2012). Examples 
of AD causative factors are amyloid-beta (Aβ) aggregation and generation of toxic 
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Aβ oligomers, the formation of tau protein fibrils within the neurons, 
neuroinflammation, excitotoxic insults, and oxidative stress (Figure 1.2).  This has 
led to the idea of multitarget-directed ligand (MTDL) in medicinal chemistry, 
molecules designed to combine functionalities or moieties needed in one molecule to 
hit multiple targets simultaneously (Nepovimova et al., 2014; Rosini et al., 2005; 
Zhang, 2005). In principle, each of the functionalities combined in a hybrid molecule 
should retain their ability to interact with their corresponding targets and 
consequently, to produce pharmacological responses which as a whole modulate the 
neurodegenerative process (Cavalli et al., 2008). Such an approach may hold the 
promise for treating a multifactorial disease such as AD. 
 
 Aaggregation and toxic soluble oligomers
(give rise to neurotoxic effects, inflammation, oxidative stress)
Presynaptic acetylcholinesterase
(hydrolysis of acetylcholine)
Excitotoxic stimulation 
(glutaminergic excitation)
Reactive astrocytes 
(Monoamine oxidase 
(Glutaminergic excitation)
Reactive microglial cells
(cytokines , TNF- )
Neuron dysfunction and loss
Oxidative stress
(Reactive oxygen species )
AChEIs 
(tacrine, galanthamine, 
donepezil, rivastigmine)
Memantine
Fibrillary tangles (tau protein) within neurons
 
Figure 1.2: A simplified diagram showing the multiple factors implicated in the 
pathogenesis of AD and the present drugs available to address them. 
 
Over the past decade, many potential multifunctional agents have been 
developed for AD treatment. The majority of these focused on the modifications of 
existing drugs with specific biological activities (Guzior et al., 2015; Nepovimova et 
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al., 2014). One of the most widely adopted designs in this approach was a dual- 
binding AChEI in which modification was made on the existing AChEIs with 
additional biological properties such as Aβ anti-aggregating activity (Bajda et al., 
2011; Giacobini, 2004; Pepeu and Giovannini, 2009). Previous studies showed that 
the peripheral anionic site (PAS) of the enzyme acetylcholinesterase (AChE) can 
induce the formation of Aβ fibrils (Bartolini et al., 2003; Inestrosa et al., 1996); 
therefore, dual-binding AChEI that is able to bind to both the catalytic and peripheral 
sites of the enzyme could simultaneously inhibit the hydrolysis of acetylcholine and 
block the Aβ-aggregating action of the enzyme (Dinamarca et al., 2010; Johnson and 
Moore, 2006). In an attempt to examine new dual-binding AChEIs, Tang and co-
workers (2011) synthesized a series of novel compounds bearing tacrine and 
oxoisoaporphine moieties linked by an aminoalkyl tether (Figure 1.3). In this 
approach, tacrine acts as catalytic-site inhibitor and oxoisoaporphine as a PAS 
inhibitor of AChE. All the synthesized compounds were found to be AChEIs, with 
IC50 values in the nanomolar range (3.4 to 910 nM) and showed inhibitory activities 
(35.5 - 85.8 %) on self-induced Aβ aggregation at 10 µM (Tang et al., 2011). 
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Figure 1.3: Structure of tacrine heterodimers with promising AChE and Aβ 
aggregation inhibitory activity (Tang et al., 2011). 
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Another successful approach of multifunctional agents based on dual-binding 
AChEI is the donepezil-tacrine hybrid compound. In 2010, a series of AChE and Aβ 
aggregation inhibitors was synthesized by Camps and co-workers by combining both 
donepezil and tacrine molecules, linked by a variety of spacer subunits (Figure 1.4). 
All compounds of this series were able to inhibit the human AChE and 
butyrylcholinesterase (BuChE) in the nanomolar range together with several 
compounds showing multipotencies by significantly inhibiting the AChE-induced Aβ 
aggregation at the concentration of 100 μM (Camps et al., 2010). 
 
N
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Figure 1.4: Structure of tacrine-donepezil hybrid compound with selective AChE and 
AChE-induced Aβ aggregation inhibitory activities (Camps et al., 2010). 
 
In another example, Bolea and co-workers (2011) reported a series of 
donepezil-based hybrid compounds capable of interacting simultaneously with 
cholinesterases (ChE) and monoamine oxidase (MAO), two targets related to AD 
and other neurodegenerative diseases. The structural design was based on the 
combination of the benzylpiperidine moiety of donepezil and indolylpropargyl amine 
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subunit present in the structure of monoamine oxidase inhibitors (MAOIs) connected 
by methylene chains of various lengths. Among the compounds tested, a compound 
(Figure 1.5) was identified as a promising compound which showed selective 
inhibition on monoamine oxidase A (MAO-A) with an IC50 of 5.2 nM and non-
selective inhibition towards the cholinesterase enzymes in submicromolar range. In 
conjunction, this compound was also shown to be able to inhibit Aβ self-induced 
aggregation as well as AChE-induced Aβ aggregation. These results suggested that 
this compound might be a promising multitargeting drug candidate to address the 
multifactorial nature of AD (Bolea et al., 2011). 
 
N
O
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Me
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Indolyl propargylamine
Benzyl piperidine
 
Figure 1.5: Structure of donepezil-propargylamine hybrid compound with dual 
ChE/MAO inhibitory activity (Bolea et al., 2011). 
 
Aside from this, more interesting multitarget-directed ligands (MTDLs) 
designed utilising this hybrid approach include the cholinesterase inhibitors with 
neuroprotective and antioxidant activity (Fernandez-Bachiller et al., 2009; Samadi et 
al., 2011), monoamine oxidase B (MAO-B) inhibitors with metal-chelating property 
(Fernandez-Bachiller et al. 2010), and metal chelators with antioxidant activity 
(Avramovich-Tirosh et al., 2007; Zheng et al., 2009). Most of these ligands have 
been shown to display promising biological activity in vitro and proved to be 
superior to those of one-target specific drugs. Interestingly, several studies also 
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suggested that MTDLs may give rise to neuroprotective effect (Bajda et al., 2011; 
Bolea et al., 2013; Minarini et al., 2012). Such a desirable effect has been attributed 
to the combination of two or more functionalities in the hybrid molecules enabling 
them to intervene concertedly on several biological pathways. 
 
1.1.4 The importance of drug-like properties 
Drug discovery is a complex and demanding process, involving many disciplines and 
investigations into various aspects, often with complications on the road to realize a 
successful drug. In the earlier history of drug discovery, the trend in industry practice 
was to optimize the biological target activity or potency of the drug candidate first. 
Little attention was given to the bioavailability and pharmacokinetic properties of the 
potent compounds. These aspects were only addressed in the later stages of 
development.  This was one of the reasons many compounds with high potencies 
failed in clinical trials due to poor pharmacokinetic profiles and bioavailability 
(Lipinski, 2000). In the case of drugs developed to treat CNS diseases such as AD, of 
the many potential compounds in development, only 2 % are able to enter the brain 
in sufficient concentrations to produce the desired therapeutic effect (Pardridge, 
2001). These clinical failures marked a tremendous loss in terms of money, research 
effort, and time.  
 
In recent years, considerable attention has been placed on assessing drug-like 
properties during the early phase of discovery. These drug-like properties include 
absorption, distribution, metabolism, elimination and toxicity (ADMET) in addition 
to the other physicochemical aspects to ensure the pharmacokinetic feasibility of 
compounds brought forth during development (Di and Kerns., 2003; Liu et al., 
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2004). The term “drug-like” is a qualitative concept used in drug design to describe 
certain intrinsic properties (structural, physicochemical, biochemical and 
pharmacokinetic) of a compound that would contribute to its bioavailability 
(availability in the system) and its availability in the CNS for drugs aimed for 
treating CNS diseases (Kerns and Di, 2008; Li, 2005). Looking for and optimizing 
drug-like features in the molecules synthesized during the early part of discovery 
would be beneficial in ensuring quality, pharmacokinetically sound (and not any) 
compounds are being studied throughout the various stages of development.  
 
Many high-throughput in vitro assays have been developed over the past 
decade for evaluating drug-like properties in order to avoid unnecessary complexities 
associated with animal models and to minimize the time and cost needed to screen 
large numbers of target compounds (Di et al., 2004; Liu et al., 2004). These assays 
measure the fundamental physicochemical and biochemical properties which 
determine the higher level properties such as the pharmacokinetics of a drug (Li, 
2004). They include blood-brain barrier permeability assays, gastrointestinal 
permeability assays, plasma stability assay, solubility assay, and liver microsomal 
stability assay that are able to sort out candidates with acceptable drug-like properties 
in the earlier drug design phase with fewer resources and in a shorter amount of time 
(Di et al., 2003; Kerns and Di, 2008; Li, 2005). Moreover, these methods also 
showed good correlation with in vivo findings and could reflect the in vivo 
pharmacokinetic condition (Li, 2005). Table 1.1 lists several commonly assessed 
drug-like properties and the in vitro assays used to evaluate them. 
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Table 1.1: Selected drug-like properties and their in vitro methods of evaluation     
(Di and Kerns, 2003). 
Drug-like Properties Methods/Assays 
Oral/gastrointestinal permeability Parallel Artificial Membrane Permeability 
Assay (PAMPA), Caco-2 cell monolayer, 
immobilized artificial membrane high 
performance liquid chromatography (HPLC), 
everted gut sac. 
 
Lipophilicity Shake flask method, reversed phase HPLC, 
capillary electrophoresis. 
 
Blood-brain barrier permeability PAMPA-BBB, cell-based method. 
 
Metabolic stability Liver microsomes, S9 fraction, cytosol, 
hepatocytes. 
 
Toxicity Cell toxicity, hERG block assays, zebrafish. 
 
CYP450 inhibition and induction Liver microsomes, hepatocytes. 
 
 
In order to design a compound with drug-like properties, the Lipinski’s rule 
of five or simply Rule of five (RO5) plays a guiding role, whereby it states that a 
drug-like molecule in general should have less than 5 hydrogen bond donors and 10 
hydrogen bond acceptors, a molecular mass less than 500 Da, and an octanol-water 
partition coefficient (log P) value less than 5 (Lipinski, 1997). Early evaluation of a 
chemical structure as suggested by the RO5 would allow one to select the possible 
drug candidates that would be more drug-like for further pharmacological testing 
(Lipinski, 2004). This rule of thumb together with the assays for evaluating drug-like 
properties  are used to drive the design, synthesis, selection, and optimization of 
compounds in conjunction with the main biological activity evaluation. 
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1.2 Overview of aurones and their AD-related activities 
Aurones (2-benzylidenebenzofuran-3-(2H)-ones) are small molecules belonging to 
the flavonoid family that are naturally present as bright yellow pigments in fruits and 
flowers of certain terrestrial and marine plants (Harborne et al., 1988). Naturally 
occurring aurones derivatives are often found as their hydroxylated, methoxylated or 
glycosylated forms (Beney et al., 2001). Although aurones are structurally related to 
the other subclasses of flavonoids (flavones, isoflavones and chalcones), aurones 
hold a unique place in nature due to the remarkably low quantities present in plants 
(Haudecoeur and Boumendjel, 2012). 
 
O
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Figure 1.6: The aurone scaffold. 
 
Ever since the first review by Boumendjel (2003), aurones have gained 
considerable attention as a “privileged structure” due to its promising utility in many 
medicinal chemistry projects (Boumendjel, 2003; Haudecour and Boumendjel, 2012; 
Zwergel et al., 2012). Aurones have been found to possess antiproliferative effect in 
cancer cells (Lawrence et al., 2003), anti-tyrosinase activity (Okombi et al., 2006), 
anti-viral activity (Liu et al., 2008), anti-microbial activity (Bandgar and Patil, 2010), 
antimalarial activity (Souard et al, 2010; Carrasco et al., 2014), and are potential 
chemopreventive agents via the induction of the cytoprotective NADP(H) Quinone 
Oxidoreductase 1 (NQO1) (Lee et al., 2010). More recent studies revealed that 
aurones possess anti-inflammatory activity by reducing the production of nitric oxide 
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and prostaglandin E2 (Shin et al., 2011), and were potent inhibitors of the breast 
cancer resistance protein ABCG2 (Sim et al., 2011) and Hepatitis C Virus RNA 
Polymerase (Haudecoeur et al., 2012; Meguellati et al., 2014).  
 
Sheng and co-workers (2009) were the first to report AD related activities of 
synthetic aminomethylaurones through AChE inhibition. Most of the synthesized 
aurones demonstrated a high inhibition towards AChE with IC50 in micromolar range 
(Sheng et al., 2009). The authors also proposed that the π-π stacking interaction of an 
aurone planar ring system could be a reason for the enhanced AChE inhibitory 
activity of the aurones (Sheng et al., 2009). In another investigation, a series of 6-
alkoxy aurone derivatives all possessing pyridinium as the nitrogen-bearing motif 
showed moderate to high AChE inhibition activities (Nadri et al., 2010). However, 
these aurones were focused mainly on the cholinesterase inhibitory activity and were 
not designed for multitargeting purposes. In addition, aurones have also been 
reported to exhibit high binding affinity for Aβ aggregates in vitro (Maya et al., 
2009) and more recently showing MAO inhibitory activity (Morales-Camilo et al., 
2015). These reported activities provide interesting leads to exploit the scaffold in the 
development of novel multitargeting anti-Alzheimer's agents.  
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Figure 1.7: Aurones with reported acetylcholinesterase inhibitory activity. 
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1.3 Problem statement and hypotheses 
The purpose of this thesis is to investigate the potential of aurones as neuroprotective 
agents via a multi-target directed ligand design while placing equal emphasis to 
maintain a balanced drug-like profile particularly their metabolic stability and ability 
to permeate the blood-brain barrier. Numerous MTDLs have been developed and 
were shown to be have potent multi-faceted activities (Bajda et al., 2011; Guzior et 
al., 2015; Pisani et al., 2011). However, despite having high potencies and strong 
binding affinities for their target proteins (many in the nanomolar range), these 
ligands were generally bulky, had high molecular weights (> 500 Da), and were 
tethered hybrids of two drug molecules as can be observed from several MTDL 
examples cited in Section 1.1.3. Such structural designs cast doubts about their drug-
like properties. Large molecular weights in these compounds could hinder their 
ability to permeate the blood-brain barrier which is necessary for a CNS-active 
compound while high lipophilicity which came with their large size may attract high 
liver metabolism and clearance particularly by the phase 1 cytochrome P450 
(CYP450) enzymes. It can be argued that in the design of these hybrid MTDLs, 
drug-like considerations (which are necessary for the development of CNS drugs) 
have been overlooked in achieving high target protein affinities and multitarget 
potencies. 
 
To develop a novel multipotent anti-Alzheimer drug that retains good drug-
like properties (metabolic stability and blood-brain barrier permeability), the aurone 
platform was utilised in the present investigation. The aurone scaffold with a tenable 
molecular weight of 222.24 Da and a topological polar surface area (26.3 Å2) would 
provide a suitable foundation for which to introduce additional key functionalities 
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while maintaining reasonable molecular weight and polar surface area in compliance 
with the RO5 (Lipinski, 1997; 2000). Over the past decade, the aurone scaffold has 
gained importance as a “privileged structure” due to its prevalence in many 
pharmacologically active compounds (Boumendjel, 2003; Zwergel et al., 2012). It is 
proposed that by incorporating selected structural motifs (various amines and 
carbamate) from two established Alzheimer drugs (rivastigmine and donepezil) into 
the scaffold, a novel multitargeting AChEI that has additional mechanism(s) of 
action may be uncovered. It would also seem likely that the proposed multitargeting 
aurones may exhibit neuroprotective effect, as has been observed in studies on other 
MTDLs (Bajda et al., 2011; Bolea et al., 2013; Minarini et al., 2012). A promising 
aurone obtained from this study would provide the tool to investigate this premise. 
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Figure 1.8: Selected structural motifs (basic amine and carbamate) from donepezil 
and rivastigmine used in the present study. 
 
In addition to examining the pharmacological potential of the aurones,  it is 
also important to gain accurate data on their drug-like properties as such information 
is needed to identify an optimal compound with a combination of good 
activity/potency and favourable pharmokinetic profile (metabolic stability, blood-
brain barrier permeability). Little is known about the drug-like properties of aurones, 
particularly their stability in the face of phase 1 CYP450 liver clearance and their 
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ability to permeate the blood-brain barrier, important features in developing a CNS-
active compound. It is hypothesized that the close resemblance between the aurone’s 
benzofuranone and the pharmacokinetically optimized donepezil’s indanone might 
give rise to favourable drug-like properties in the target aurones in addition to their 
“streamlined” (small molecular weights and polar surface area) design. Furthermore, 
the proposed introduction of amines and carbamate moieties into the scaffold may 
influence the physicochemical properties of the scaffold and hence their drug-like 
potential. 
 
1.4 Objectives of study 
To verify the aforementioned hypotheses, the specific objectives of the study are as 
follow: 
(i) To design and synthesize a series of aurone derivatives incorporating the 
selected structural motifs from the known AChEIs donepezil and rivastigmine. 
(ii) To elucidate the structure-activity relationship of the aurones with respect to 
their cholinesterase inhibitory activity as well as their mode of binding. 
(iii) To investigate the multitargeting potential of the aurones in two AD-related 
targets (monoamine oxidase and Aβ aggregation) and their respective binding 
mechanisms. 
(iv) To evaluate the drug-like properties of selected aurones using in vitro 
pharmacokinetic assays (metabolic stability, blood-brain barrier permeability). 
(v) To investigate the neuroprotective effects of the most promising aurone in two 
Caenorhabditis elegans (C.elegans) neurodegeneration models. 
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CHAPTER 2 
 
DESIGN AND SYNTHESIS OF TARGET COMPOUNDS 
 
2.1 Introduction  
This chapter describes the design and synthesis of target compounds for the 
evaluation of potential neuroprotective properties based on their anti-cholinesterase 
activity. These compounds possess the aurone scaffold with modifications at rings A 
and B with various basic amines and carbamate functionalities. The rationale 
underlying the design, chemical considerations of their synthesis and the 
experimental methods are presented. The structures of the synthesized compounds 
were identified by proton-1 (1H) and carbon-13 (13C) nuclear magnetic resonance 
(NMR) spectroscopy, and their mass spectra. Spectroscopic data, melting points, 
yields and purities of each compound are listed in Appendix 1. 
 
2.2 Rationale of target compound design 
The aurone scaffold was chosen in this investigation owing to the close resemblance 
of its benzofuranone core with the indanone of the clinically used Alzheimer drug 
donepezil (Figure 2.1). Donepezil is a well-tolerated, orally bioavailable 
acetylcholinesterase inhibitor for the treatment of AD (Sugimoto et al., 2002; 
Wilkinson, 1999).  It serves as a lead for further modifications on the aurone scaffold 
to uncover novel compounds with a similar pharmacokinetic profile. Furthermore, 
studies on a series of pyridinium aurone derivatives synthesized as 
acetylcholinesterase inhibitors revealed that some of these compounds exhibited high 
anti-cholinesterase activity (Nadri et al., 2013; Nadri et al., 2010). In addition, 
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aurones have been developed as probes for imaging Aβ plaques using single photon 
emission computed tomography (SPECT) that showed high affinity for Aβ 
aggregates (Ono et al., 2007) suggesting a potential multi-targeting property in the 
scaffold. 
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Figure 2.1: The aurone scaffold and the structures of AChEIs donepezil and 
rivastigmine. 
 
In this study, a total of forty-one target compounds were synthesized and 
grouped into six series based on the modifications at rings A and B of the aurone 
scaffold. Series 1 and 2 consist of 6-hydroxyaurones and 6-methoxyaurones 
respectively with different substituents at the 4'-position of the ring B (Table 2.1 and 
2.2). They were introduced because such oxygenated aurones have been reported to 
exhibit multiple bioactivities including anti-inflammatory properties (Shin et al., 
2011), a desirable feature in developing a multi-targeting agent. Moreover, hydroxyl 
and methoxyl groups would provide a good comparison between the two series with 
regard to their lipophilicities and hydrogen bond donor and acceptor properties. 
Series 3 comprises of aurones with “reversed” functionalized equivalents of Series 2 
in which the various substituents are placed at the 6-position of ring A while the 
methoxyl group is at the 4'-position of ring B (Table 2.3). They provide suitable 
comparisons with Series 2 and Series 5 by which to explore the placement of the 
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amine or carbamate moieties at the other end of the scaffold. Series 4 aurones are 
akin to Series 3 with the functionalization at ring A but with a 3', 4', 5'-trimethoxy 
motif at ring B (Table 2.4). This modification was inspired by a report on a series of 
multipotent AChEIs in which the use of this motif gave rise to potent inhibitors 
(Belluti et al., 2005). Series 5 are 6-diethylcarbamoylaurones with the amine 
functionalities at ring B to examine the effect of having the carbamate moiety at ring 
A (Table 2.5). Series 6 aurones are chlorinated equivalents of Series 2 where one 
chlorine is placed at positions ortho and meta to the amine functionality at ring B 
(Table 2.6). This series serves to assess whether the placement of an electron-
withdrawing group (such as chlorine) near a potentially labile site can increase the 
metabolic stability of the compounds. 
 
As for the type of substituents, they were limited to tertiary amines such as 
dimethylamino-, diethylamino-, pyrrolidine, and piperidine. The rationale underlying 
this choice was because most centrally active AChEIs such as donepezil, 
galanthamine and recently synthesized derivatives (Pan et al., 2014; Yan et al., 2012) 
hold basic, ionisable nitrogen-containing moieties which contribute to their activities 
and pharmacokinetic properties. Carbamate functionality (diethylcarbamate) 
borrowed from the known AChEI rivastigmine (Figure 2.1) and xanthostigmine 
derivatives (Rampa et al., 2001) is another group introduced into the design of the 
present aurones. The incorporation of the aforementioned amines and carbamate to 
the aurone scaffold is expected to influence the anti-cholinesterase activity of the 
target compounds.  
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Table 2.1: Structures of compounds in Series 1 
Compound R1 % Yield 
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Table 2.2: Structures of compounds in Series 2 
Compound R1 % Yield 
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O
O
R1
A
H3CO
6
 
 
2-1 
 
O
N CH3
CH3
B
 
 
53 
 
2-2 
 
O
N
B
 
 
26 
 
2-3 
 
O
N
B
 
 
19 
 
2-4 
 
N
CH3
CH3B
 
 
42 
 
2-5 
 
N
CH3
CH3
B
 
 
47 
 
2-6 
 
N
B
 
 
 
38 
 
2-7 
 
O
B
N
CH3
CH3
 
 
 
33 
 
2-8 
 
B
OCH3
 
 
36 
 
2-9 
 
B
OH
 
 
 
98 
 
2-11 
 
B
O
O
N
CH3
CH3
 
 
20 
 
23 
 
Table 2.3: Structures of compounds in Series 3 
Compound R1 % Yield 
Series 3 
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Table 2.4: Structures of compounds in Series 4 
Compound R1 % Yield 
Series 4 
O
O
A
R1
OCH3
B
H3CO
OCH36 3'
4'
5'
 
 
 
4-1 
 
O
N CH3
CH3  
 
 
42 
 
4-2 
 
O
N
 
 
 
59 
 
4-3 
 
O
N
 
 
 
70 
 
4-7 
 
O N
CH3
CH3 
 
 
39 
24 
 
 
Table 2.5: Structures of compounds in Series 5 
Compound R1 % Yield 
Series 5 
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